The stock of Novavax Inc. (NASDAQ:NVAX) last traded at $8.05, down -2.19% from the previous session.
Data from the available sources indicates that Novavax Inc. (NASDAQ:NVAX) is covered by 6 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $5.00, we find $15.00. Given the previous closing price of $8.23, this indicates a potential upside of 82.26 percent. NVAX stock price is now 1.84% away from the 50-day moving average and -18.60% away from the 200-day moving average. The market capitalization of the company currently stands at $776.91M.
In total, 1 analysts have assigned it a hold rating, and 3 have given it a buy rating. Brokers who have rated the stock have averaged $20.60 as their price target over the next twelve months.
With the price target maintained at $15, B. Riley Securities recently Upgraded its rating from Neutral to Buy for Novavax Inc. (NASDAQ: NVAX).
In other news, Glenn Gregory M, President, R&D bought 1,000 shares of the company’s stock on Mar 10. The stock was bought for $6,500 at an average price of $6.50. Upon completion of the transaction, the President, R&D now directly owns 14,473 shares in the company, valued at $0.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07, President, R&D Glenn Gregory M bought 2,000 shares of the business’s stock. A total of $14,088 was incurred on buying the stock at an average price of $7.04. This leaves the insider owning 13,473 shares of the company worth $0.11 million. Insiders disposed of 22,139 shares of company stock worth roughly $0.18 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NVAX stock. A new stake in Novavax Inc. shares was purchased by ALLIANZ ASSET MANAGEMENT GMBH during the first quarter worth $3,174,000. ADAGE CAPITAL PARTNERS GP, L.L.C. invested $2,415,000 in shares of NVAX during the first quarter. In the first quarter, POINT72 MIDDLE EAST FZE acquired a new stake in Novavax Inc. valued at approximately $1,792,000. SKAANA MANAGEMENT L.P. acquired a new stake in NVAX for approximately $1,223,000. STRS OHIO purchased a new stake in NVAX valued at around $680,000 in the second quarter. In total, there are 307 active investors with 47.00% ownership of the company’s stock.
With an opening price of $8.24 on Friday morning, Novavax Inc. (NASDAQ: NVAX) set off the trading day. During the past 12 months, Novavax Inc. has had a low of $5.61 and a high of $37.88. The fifty day moving average price for NVAX is $7.91 and a two-hundred day moving average price translates $9.83 for the stock.
The latest earnings results from Novavax Inc. (NASDAQ: NVAX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.58, beating analysts’ expectations of -$1.39 by 1.97. This compares to -$6.53 EPS in the same period last year. The net profit margin was -36.70% and return on equity was 82.30% for NVAX. The company reported revenue of $424.43 million for the quarter, compared to $185.93 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 128.28 percent. For the current quarter, analysts expect NVAX to generate $226M in revenue.
